

Pyocyanin: A Powerful Inhibitor Of bacterial Growth and Biofilm Formation

Patrick Abou Raji El Feghali and Tarek Nawas*

Department of Natural Sciences, School of Arts and Sciences, Lebanese American University, Beirut, Lebanon

Article Info

***Corresponding author:**

Tarek Nawas

Department of Natural Sciences
School of Arts and Sciences
Lebanese American University
Beirut, Lebanon
Tel: +961 03 374619
E-mail: tnawas@lau.edu.lb

Received: December 6, 2018

Accepted: December 12, 2018

Published: December 18, 2018

Citation: Raji El Feghali PA, Nawas T. Pyocyanin: A Powerful Inhibitor Of bacterial Growth and Biofilm Formation. *Madridge J Case Rep Stud.* 2018; 2(2): 101-107.
doi: 10.18689/mjcrs-1000125

Copyright: © 2018 The Author(s). This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Published by Madridge Publishers

Abstract

Pyocyanin, a pigment naturally produced by most *Pseudomonas aeruginosa* strains and noted to have a role in the wellbeing of the organism and its pathogenicity, was studied for its role as an inhibitor of bacterial growth and biofilm formation of many clinical bacterial isolates. The organisms included in the study were 33 isolates of 11 different bacterial species. The results showed that most of the Gram-positive isolates from the 3 species included in the study: *Staphylococcus aureus*, *Staphylococcus saprophyticus* and *Enterococcus fecalis* were inhibited at low concentrations of pyocyanin. The results varied for the Gram-negative organisms tested. Whereas the growth of the *Escherichia coli*, *Citrobacter koseri*, *Enterobacter cloacae* and *A. baumannii* isolates was clearly inhibited even by low concentrations of pyocyanin, the growth of *Klebsiella pneumoniae*, *Proteus mirabilis* and *Morganella morganii* was not affected even by higher concentrations of pyocyanin. The methanol extract of the pigment was highly effective in preventing the biofilm forming ability of all *S. saprophyticus*, *A. baumannii*, *E. cloacae* and *K. pneumoniae* isolates, 3 of the 4 *P. mirabilis* isolates and 2 of the 5 *E. coli* isolates. All the other isolates tested, also showed a moderate antibiofilm activity. This study revealed that pyocyanin has a powerful inhibitory effect on the bacterial growth and/or biofilm forming ability of the numerous clinically significant isolates tested, a characteristic that can prove valuable in developing new drugs for the treatment and prevention of different bacterial infections, once its safety for regular use has been assessed.

Keywords: Pyocyanin; Antibacterial activity; Inhibition of biofilm formation; Bacterial pigment; *Pseudomonas aeruginosa*.

Introduction

Pseudomonas aeruginosa is a proteobacterial Gram-negative bacillus placed in the family *Pseudomonadaceae* based on the analysis of conserved macromolecules like the 16S ribosomal RNA [1]. Its metabolism relies mainly on aerobic respiration. It is motile and almost all of its strains are motile by the single polar flagellum that they possess [2, 3]. *P. aeruginosa* can colonize many natural and artificial areas including soil, water, etc [4, 5]. This is due to its ability to live not only in atmospheric conditions, but also in hypoxic atmospheres. Special features, including the different colors and pigments it produces, make *P. aeruginosa* easily recognizable. These pigments include pyocyanin (blue-green), pyoverdine (yellow, green and fluorescent), pyomelanin (light brown) and pyorubrin (red-brown) [6, 7]. Pyocyanin, or the 'blue pus' (from *pyocyanus*), is produced by around 90-95 % of all *P. aeruginosa* isolates (Fordos, 1863; Gessard, 1984; Ran et al., 2003) [8, 9, 10]. Pyocyanin production is favored in media where iron is not present in high amounts, but it plays a major role in iron metabolism. Its mechanism of action relies mainly on its ability to reduce and release the iron from transferrin; this is important since *P. aeruginosa* relies crucially on iron for growth (Cox, 1986) [11].

Pyocyanin is a natural derivative of the nitrogen-containing heterocyclic compound called phenazine. It is a redox active secondary metabolite and soluble in chloroform. At the genetic level, 7 genes, namely *phz C*, *D*, *E*, *F*, *G*, *M* and *S*, were identified to be responsible for the biosynthesis of pyocyanin in *P. aeruginosa*. These loci were found in all *Pseudomonas* spp [12, 13, 14]. The *phz M* and *phz S* genes were found to be the main genes responsible for converting phenazine-1-carboxylic acid to pyocyanin. However, little information about the enzymes encoded by the *phz M* and *phz S* genes is known.

The antibacterial effect of pyocyanin was first reported in 1940, when its effect on the inhibition growth of *Escherichia coli* was tested, the pigment was named colicin back then [15]. The purified form of pyocyanin exhibited a concentration dependent bactericidal effect [16]. The mechanism behind the antibacterial effect of pyocyanin was investigated and it was concluded that pyocyanin prevents the cells from performing their active metabolic transport process by interacting with the cell membrane respiratory chain [17]. When *E. coli* was treated with pyocyanin, the oxygen supply to these cells was depleted, in addition to H₂O₂ production, and diversion of the electron flow, causing toxicity to *E. coli* cells [18]. Pyocyanin was also reported to have an anti-staphylococcal effect, for pyocyanin extracted from *P. aeruginosa* isolated from the sputum of Cystic fibrosis (CF) patients inhibited the growth of *Staphylococcus aureus* [19]. Pyocyanin also showed a bactericidal effect against *Salmonella* Paratyphi and *E. coli* [20]. It is now accepted that pyocyanin accounts for 90-95% of the ability of *P. aeruginosa* to inhibit bacterial growth. In fact, pyocyanin isolated from *P. aeruginosa* 4B strain, was shown to exhibit an antibacterial effect against food spoilage bacteria like *Listeria monocytogenes* and *Bacillus cereus* [21]. In addition, when pyocyanin from *P. aeruginosa* DSO-129 was produced in a low cost micro-bioreactor with high processing, it was shown to have an inhibitory effect against several microorganisms including *S. aureus*, *Staphylococcus epidermidis*, *Bacillus subtilis*, *Micrococcus luteus* and *saccharomyces cerevisiae* [22].

The inhibition of fungi like *C. albicans* by pyocyanin was also clinically proven in patients with lung infections, as infection by *C. albicans* recurred after pyocyanin suppression [23]. Furthermore, *Aspergillus fumigatus* and *Candida albicans*, isolated from the sputum of Cystic fibrosis patients, were also inhibited by pyocyanin isolated from *P. aeruginosa* [24].

This study aimed at determining whether pyocyanin had the ability to inhibit the growth and/or the formation of biofilms by different Lebanese clinical isolates.

Materials and Methods

Bacterial isolates

The bacterial isolates used in the study were clinical isolates courteously provided by the Clinical Microbiology Laboratory of the Lebanese American University Medical Center- Rizk Hospital (LAUMC- RH) and 4 isolates from a community health center referred to in the study as public isolates (PI). In total, the isolates tested were the following: 5 isolates of *Escherichia coli*, 5 isolates of *Staphylococcus aureus*, 4 isolates of *Proteus mirabilis*, 4 isolates

of *Klebsiella pneumoniae*, 4 isolates of *Enterobacter cloacae*, 3 isolates of *Citrobacter koseri*, 2 isolates of *Staphylococcus saprophyticus*, 2 isolates of *Enterococcus faecalis*, 2 isolates of *Acinetobacter baumannii*, and 2 isolates of *Morganella morganii*. The identity of the isolates was confirmed standard tests [25]. The identity of the Gram-negative bacilli was confirmed using the API 20E test strips (Biomerieux-France).

Aqueous extraction and purification of pyocyanin and testing for antibacterial effect

Aqueous extraction and purification of pyocyanin

pyocyanin was extracted using the method previously described by Wilson et al. (1987), [26] but as amended by Abou Raji El Feghali and Nawas (2018) [27]. Major amendments were related to media used to grow the organism, incubation and holding time and the addition of a step to the acid/base extraction, to optimize the yield of pyocyanin.

Antibacterial activity of pyocyanin

The antibacterial effect of the aqueous extracts was performed by using the well agar diffusion method using Mueller-Hinton agar (MHA) as recommended [28]. Using a sterile swab, the MHA plates were seeded with the organism taken from a saline tube containing the fresh test organism and adjusted to have a turbidity equivalent to that of a 0.5 McFarland standard. Using a cork borer, an 8.5 mm well was placed in the middle of the plate. The well was filled with increasing volumes of pyocyanin extract, from 200µl to 700µl. [29]. The plates were then incubated at 35°C for 24 h, after which the of zones of inhibition of growth around the wells (whenever present) were measured using a caliper. The reported results were the averages of the diameters measured for each of the zones of inhibition of growth that surrounded the wells for each concentration of the tested extract for each test organism.

Methanol extraction and testing for anti-biofilm activity

Preparation of the methanol extract

In the extraction and purification procedure used in the study, [27] and in the final steps after the dissolution of pyocyanin crystals with chloroform, 0.05M HCL was added to the mixture and the red aqueous phase extracted and neutralized drop by drop by 0.05M NaOH until the blue color was recovered. Afterwards, methanol was added to the mixture making it 80% of the total volume.

Effect of the methanol extract on biofilm formation

Preparation of the bacterial isolates

From fresh agar plates, each of the test organisms was used to inoculate a 10 ml trypticase soy broth (TSB) tube with 1% glucose. The inoculated TSB tubes were left in the incubator at 37°C for 24 h, after which, the culture tubes were diluted 100 times with fresh media.

Effect of the extracts on biofilm formation

To test for the formation of biofilms by the isolates and possible inhibition of the process by the methanol extract of pyocyanin, a method very slightly modified from that used by Mathur et al. (2006) was used [30]. The methanol extract was

added to specified test wells of the 96 well flat-bottom tissue culture plates and the plates were left to dry in the incubator under aseptic conditions. Upon drying, 200 µl of sterile TSB were added to all the wells of the plates with 10 µl of the diluted cultures (previous section) and incubated at 35°C for 24 h. The contents of the wells were then gently discarded by repeated soft tapping, after which the wells were washed with phosphate buffered saline (PBS, pH of 7.2) several times. Then, 0.2% sodium acetate was added to fix any biofilms that may have formed, and a 0.1% solution of crystal violet was finally added to stain the biofilms, when present. Excess stain was then removed with deionized water and the plates were left to dry. The optical densities were later determined by using a microplate auto-reader at 570 nm wavelength. To have a precise result, each of the test samples (and controls) was performed in 16 wells. The reported optical densities, in the study, were the averages of the 16 readings of each sample.

Results

The aqueous extract of pyocyanin showed clear antibacterial activity against a wide range of the bacteria tested. As is obvious from Table 1, of the Gram-positive isolates, all the 5 *S.aureus* isolates were inhibited at a volume of 200 µL of the extract, while the 2 *S.saprophyticus* and 2 *E. fecalis* isolates were also inhibited, however, one of each was inhibited by a volume of 200 µL, while the others by a volume of 300 µL. For all,

however, the antibacterial effect was shown to increase with the increase of volume of the extract added. On the other hand, the results varied for the Gram-negative isolates, for whereas the growth of *E. coli*, *C. koseri*, and *E. cloacae* and *A. baumannii* isolates was clearly all inhibited either by a volume of 200 µL or a volume of 300 µL, (with a clear increase in antibacterial activity with increase in volume of pyocyanin tested), yet the growth of all the *K. pneumoniae*, *P. mirabilis* and *M. morgani* isolates was not affected by the pyocyanin extract even with the maximal volumes of pyocyanin used in this study (Table 1).

As to the ability of pyocyanin to inhibit the biofilm formation of the different isolates, Table 2 represents the optical densities read for each of the samples tested and their controls. The same results are also represented graphically for individual species in Figures 1 to 10. The results clearly indicated that all the clinical isolates were capable of forming biofilms on the bottom of the tissue culture plates. The power of the pyocyanin methanol extract to affect the ability of the isolates to form biofilms is also obvious. The pyocyanin methanol extract was highly effective in preventing the biofilm forming ability of all *S. saprophyticus* (Figure 2), *A. baumannii* (Figure 6), *E. cloacae* (Figure 9) and *K.pneumoniae* (Figure 10) isolates, 3 of the 4 *P.mirabilis* isolates (Figure 5), 2 of the 5 *E.coli* isolates (Figure 4), 1 of the 2 *E. fecalis* isolates (Figure 3) and 1 of the 5 *S. aureus* isolates (Figure 1). All the other isolates in this study including the *M.morgani* and *C.koseri* isolates, however, showed a moderate antibiofilm activity (Figures 7&8).

Table 1. Diameters, in millimeters, of the zones of inhibition of growth of the bacterial isolates, using different concentrations of the aqueous extract of pyocyanin. X: No zone of inhibition. PI: Public isolate, MDR: multidrug resistant, ESBL: extended spectrum beta lactamase producing

Isolates	Control	200 µL	300 µL	400 µL	500 µL	600 µL	700 µL
Gram positive							
<i>S.aureus</i> : isolate 1	X	27.0	29.7	32.3	34.0	35.7	38.0
<i>S.aureus</i> : isolate 2 (PI)	X	27.7	31.0	34.3	35.7	37.0	38.3
<i>S.aureus</i> : isolate 3	X	28.7	30.7	32.7	34.0	36.7	38.3
<i>S.aureus</i> : isolate 4	X	28.0	30.3	34.5	35.3	36.7	38.0
<i>S.aureus</i> : isolate 5 (MDR)	X	20.3	23.3	25.7	29.7	31.3	32.7
<i>S.saprophyticus</i> : isolate 1	X	25.0	34.0	35.3	40.3	41.7	43.3
<i>S.saprophyticus</i> : isolate 2	X	X	26.7	30.0	34.3	36.7	39.7
<i>E.fecalis</i> : isolate 1	X	27.7	35.7	37.7	39.0	43.0	48.0
<i>E.fecalis</i> : isolate 2 (MDR)	X	X	22.0	25.0	29.3	32.7	35.7
Gram negative							
<i>E.coli</i> : isolate 1 (PI)	X	23.3	28.7	31.7	33.3	35.7	37.7
<i>E.coli</i> : isolate 2 (ESBL)	X	25.7	29.3	31.3	33.7	35.0	36.3
<i>E.coli</i> : isolate 3 (ESBL)	X	X	28.0	31.3	33.0	34.3	35.7
<i>E.coli</i> : isolate 4 (Non ESBL)	X	X	25.0	26.7	28.0	30.0	31.7
<i>E.coli</i> : isolate 5 (Non ESBL)	X	X	30.3	31.7	33.0	36.0	37.3
<i>P.mirabilis</i> : isolate 1	X	X	X	X	X	X	X
<i>P.mirabilis</i> : isolate 2	X	X	X	X	X	X	X
<i>P.mirabilis</i> : isolate 3	X	X	X	X	X	X	X
<i>P.mirabilis</i> : isolate 4 (PI)	X	X	X	X	X	X	X
<i>M.morgani</i> : isolate 1	X	X	X	X	X	X	X
<i>M.morgani</i> : isolate 2	X	X	X	X	X	X	X
<i>C.koseri</i> : isolate 1	X	X	21.7	25.0	26.3	28.3	31.7
<i>C.koseri</i> : isolate 2	X	X	20.3	25.7	27.3	28.0	29.7
<i>C.koseri</i> : isolate 3	X	X	21.3	22.7	25.7	27.3	30.3
<i>E.cloacae</i> : isolate 1	X	X	21.7	28.3	30.3	33.0	34.3
<i>E.cloacae</i> : isolate 2	X	X	24.7	30.3	32.0	34.3	35.7
<i>E.cloacae</i> : isolate 3	X	21.0	22.3	25.3	28.7	30.3	34.7
<i>E.cloacae</i> : isolate 4	X	21.0	25.0	27.7	30.3	32.3	35.3
<i>K.pneumoniae</i> : isolate 1 (PI)	X	X	X	X	X	X	X
<i>K.pneumoniae</i> : isolate 2	X	X	X	X	X	X	X
<i>K.pneumoniae</i> : isolate 3	X	X	X	X	X	X	X
<i>K.pneumoniae</i> : isolate 4 (ESBL)	X	X	X	X	X	X	X
<i>A.baumannii</i> : isolate 1	X	20.3	24.7	27.3	29.0	31.3	33.3
<i>A.baumannii</i> : isolate 2	X	20.0	25.3	28.3	30.3	31.7	34.7

Table 2. Average optical density (O.D.) readings at a wavelength of 570 nm, of the different cultures tested in this study. PI: Public isolate, MDR: multidrug resistant, ESBL: extended spectrum beta lactamase producing.*: Moderate antibiofilm effect, **: High antibiofilm effect

Bacterial isolates	O.D. readings of the wells containing		
	Bacteria	Bacteria + Pyocyanin	Pyocyanin
Gram positive			
<i>S.aureus</i> : isolate 1**	0.7363	0.7082	0.4449
<i>S.aureus</i> : isolate 2 (PI)*	1.3212	1.3318	0.4627
<i>S.aureus</i> : isolate 3*	0.6334	0.7318	0.4984
<i>S.aureus</i> : isolate 4*	0.6126	0.6796	0.4249
<i>S.aureus</i> : isolate 5 (MDR)*	0.8122	0.9056	0.3669
<i>S.saprophyticus</i> : isolate 1**	0.5315	0.3135	0.3307
<i>S.saprophyticus</i> : isolate 2**	0.829	0.5086	0.4627
<i>E.fecalis</i> : isolate 1*	0.518	0.525	0.3558
<i>E.fecalis</i> : isolate 2 (MDR)**	0.6325	0.4139	0.4449
Gram negative			
<i>E.coli</i> : isolate 1 (PI)*	0.4891	0.576	0.4627
<i>E.coli</i> : isolate 2 (ESBL)*	0.595	0.6382	0.4985
<i>E.coli</i> : isolate 3 (ESBL)**	0.5161	0.4512	0.4984
<i>E.coli</i> : isolate 4 (Non ESBL)*	0.5709	0.7197	0.4494
<i>E.coli</i> : isolate 5 (Non ESBL)**	0.5368	0.5281	0.4646
<i>P.mirabilis</i> : isolate 1**	0.5021	0.4836	0.3909
<i>P.mirabilis</i> : isolate 2**	0.5697	0.5568	0.4494
<i>P.mirabilis</i> : isolate 3*	0.4518	0.4694	0.3669
<i>P.mirabilis</i> : isolate 4 (PI)**	0.7437	0.6379	0.3669
<i>M.morganii</i> : isolate 1*	0.7719	0.7977	0.4738
<i>M.morganii</i> : isolate 2*	0.4046	0.4682	0.3558
<i>C.koseri</i> : isolate 1*	0.6013	0.8197	0.5085
<i>C.koseri</i> : isolate 2*	0.8871	1.2904	0.3909
<i>C.koseri</i> : isolate 3*	0.5816	0.6194	0.4159
<i>E.cloacae</i> : isolate 1**	0.8041	0.5953	0.4159
<i>E.cloacae</i> : isolate 2**	0.6014	0.5681	0.5038
<i>E.cloacae</i> : isolate 3**	0.5822	0.5223	0.5139
<i>E.cloacae</i> : isolate 4**	0.4395	0.3839	0.3745
<i>K.pneumoniae</i> : isolate 1**	0.4556	0.4018	0.4984
<i>K.pneumoniae</i> : isolate 2**	0.4882	0.3798	0.4446
<i>K.pneumoniae</i> : isolate 3**	0.5877	0.4145	0.4159
<i>K.pneumoniae</i> : isolate 4 (ESBL)**	0.5786	0.4459	0.3802
<i>A.baumannii</i> : isolate 1**	1.4349	1.0391	0.3558
<i>A.baumannii</i> : isolate 2**	0.8056	0.6077	0.4028




Figure 1. Graphic representation of the data in Table 2. X axis: Samples (*S. aureus* isolates 1, 2(PI), 3, 4, 5 (MDR) tested for biofilm formation/inhibition; Y axis: optical density (O.D.) readings at a wavelength of 570 nm. (PI): Public isolate, (MDR): Multi Drug Resistant




Figure 2. Graphic representation of the data in Table 2. X axis: Samples (*S. saprophyticus* isolates 1 and 2) tested for biofilm formation/inhibition; Y axis: optical density (O.D.) readings at a wavelength of 570 nm.




Figure 3. Graphic representation of the data in Table 2. X axis: Samples (*E. fecalis* isolates 1 and 2 (MDR)) tested for biofilm formation/inhibition; Y axis: optical density (O.D.) readings at a wavelength of 570 nm. (MDR): Multi Drug Resistant




Figure 4. Graphic representation of the data in Table 3. X axis: Samples (*E. coli* isolates 1(PI), 2(ESBL), 3(ESBL), 4, 5) tested for biofilm formation/inhibition; Y axis: optical density (O.D.) readings at a wavelength of 570 nm. (PI): Public isolate.




Figure 5. Graphic representation of the data in Table 3. X axis: Samples (*P. mirabilis* isolates 1, 2, 3, 4(PI)) tested for biofilm formation/inhibition; Y axis: optical density (O.D.) readings at a wavelength of 570 nm. (PI): Public isolate.




Figure 8. Graphic representation of the data in Table 3. X axis: Samples (*C. koseri* isolates 1, 2 and 3) tested for biofilm formation/inhibition; Y axis: optical density (O.D.) readings at a wavelength of 570 nm.




Figure 6. Graphic representation of the data in Table 3. X axis: Samples (*A. baumannii* isolates 1 and 2) tested for biofilm formation/inhibition; Y axis: optical density (O.D.) readings at a wavelength of 570 nm.




Figure 9. Graphic representation of the data in Table 3. X axis: Samples (*E. cloacae* isolates 1, 2, 3 and 4) tested for biofilm formation/inhibition; Y axis: optical density (O.D.) readings at a wavelength of 570 nm.




Figure 7. Graphic representation of the data in Table 3. X axis: Samples (*M. morganiii* isolates 1 and 2) tested for biofilm formation/inhibition; Y axis: optical density (O.D.) readings at a wavelength of 570 nm.




Figure 10. Graphic representation of the data in Table 3. X axis: Samples (*K. pneumoniae* isolates 1, 2, 3 and 4(ESBL)) tested for biofilm formation/inhibition; Y axis: optical density (O.D.) readings at a wavelength of 570 nm.

Discussion

Previous reports noted the antibacterial and antifungal activity of pyocyanin [19, 23, 24, 31, 32]. The results of this study showed that the antibacterial effect of pyocyanin on the different Lebanese bacterial strains tested, was also evident. The Gram-positive organisms including *S. aureus*, *S. saprophyticus* and *E. fecalis* were all inhibited even using low concentrations of the aqueous pyocyanin (200 or 300 µL). A similar result was reported by Machan and his colleagues in 1991, where pyocyanin extracted from *P. aeruginosa* from cystic fibrosis (CF) patients exhibited anti-staphylococcal activity by inhibiting the growth of *S. aureus*. These results were obtained through the cross-streak test, well plate assay and growth of mixed culture [19].

Most of the Gram-negative bacteria tested in this study, namely *E. coli*, *E. cloacae*, *C. koseri* and *A. baumannii*, were also inhibited by low concentration of aqueous pyocyanin (200 or 300 µL). The antibacterial effect of pyocyanin on certain Gram negative bacteria was also previously noted and reported, and it was shown that pyocyanin had an antibacterial effect against *E. coli* and *Acinetobacter* isolates [31, 32].

It was noted in this study, however, that pyocyanin, even at the higher volumes used did not in any way affect the growth of the *K. pneumoniae*, *P. mirabilis* or *M. morgani* isolates tested (Table 1). Similar results were reported by previous studies. Sweedan in 2010, reported that *K. pneumoniae* and *P. vulgaris* were resistant to any antibacterial effect that pyocyanin may have, [31] while El-Shouny and his colleagues (2011) also reported that *K. pneumoniae* was fully resistant to any antibacterial activity that pyocyanin may have demonstrated [32].

It is also worth noting from Table 1 that the antibacterial effect of pyocyanin, on the different isolates that were susceptible to it, was concentration dependent and increased with increasing concentrations of the pyocyanin added. The diameters of the zones of inhibition of growth increased with increasing concentration of pyocyanin. The effect of pyocyanin, as an antibacterial agent, on the Gram-positive bacteria was evidently much stronger than that on the Gram-negative bacteria as was clear from comparing the diameters of the zones of inhibition of growth of the two groups (Table 1).

The mechanism through which pyocyanin exhibits its antibacterial activity was previously studied and it turned out that pyocyanin interacted with the respiratory chain of the cell membrane preventing the susceptible bacteria from performing their regular metabolic processes [17]. Furthermore, pyocyanin was toxic to the *E. coli* cells by depleting the oxygen supply to the cell, producing H₂O₂ and diverting the regular flow of electrons [18].

After reviewing the literature, it is believed that this study is the first to demonstrate the ability of pyocyanin methanol extracts to inhibit the biofilm formatting ability of several clinically important bacterial strains (Table 2 and Figures 1-10). This finding is extremely important as one of the most challenging problems in antibacterial therapy remains the difficulty in targeting bacteria that are, enclosed within formed biofilms [33].

Conclusion

This study revealed that pyocyanin produced by *P. aeruginosa* has a powerful inhibitory effect on the bacterial growth and/or biofilm forming ability of the numerous clinically significant isolates tested. Such results could be supported by future studies on the rate, frequency and type of other infections in the presence of *P. aeruginosa*, like in the case of cystic fibrosis (CF) patients. Pyocyanin may turn out to be a valuable new addition to the currently existing medications as an antibacterial drug or a chemical used in the prevention of bacterial biofilm formation. Further studies are also needed to assess the safety of using pyocyanin on hosts and their microbiota.

References

1. Glazebrook JS, Campbell RSF, Hutchinson GW, Stallman ND. Rodent zoonoses in north Queensland. *Immunol and Cell Biol.* 1978; 56(2): 147-156.
2. Moore ER, Tindall BJ, Dos Santos VAM, Pieper DH, Ramos JL, Palleroni NJ. Nonmedical: pseudomonas. In *The prokaryotes.* Springer New York. 2006; 646-703.
3. Palleroni NJ. *Pseudomonas*. In *Bergey's Manual of Systematics of Archaea and Bacteria.* Bergey's. 2015. doi: 10.1002/9781118960608.gbm00186
4. Green SK, Schroth MN, Cho JJ, Kominos SD, Vitanza-Jack VB. Agricultural plants and soil as a reservoir for *Pseudomonas aeruginosa*. *Appl microbiol.* 1974; 28(6): 987-991.
5. Suthar S, Chhimpia V, Singh S. Bacterial contamination in drinking water: a case study in rural areas of northern Rajasthan, India. *Environ Monit assess.* 2009; 159(1-4): 43-50. doi: 10.1007/s10661-008-0611-0.
6. Reyes EA, Bale MJ, Cannon WH, Matsen JM. Identification of *Pseudomonas aeruginosa* by pyocyanin production on Tech agar. *J Clin Microbiol.* 1981; 13(3): 456-458.
7. Meyer JM. Pyoverdines: pigments, siderophores and potential taxonomic markers of fluorescent *Pseudomonas* species. *Arch Microbiol.* 2000; 174(3): 135-142.
8. Fordos M. Recherches sur les matieres colorantes des suppurations bleues, pyocyanine et pyoxanthose. *CR Hebd Seances Acad Sci.* 1863; 56: 1128-1131.
9. Gessard C. On the blue and green coloration that appears on bandages. *Reviews of Infect Diseases.* 1984; 6(3): 775-776. doi: 10.1093/clinids/6.Supplement_3.775
10. Ran H, Hassett DJ, Lau GW. Human targets of *Pseudomonas aeruginosa* pyocyanin. *Proc Natl Acad Sci.* 2003; 100(24): 14315-14320. doi: 10.1073/pnas.2332354100
11. Cox CD. Role of pyocyanin in the acquisition of iron from transferrin. *Infect immun.* 1986; 52(1): 263-270.
12. Mavrodi DV, Bonsall RF, Delaney SM, Soule MJ, Phillips G, Thomashow LS. Functional analysis of genes for biosynthesis of pyocyanin and phenazine-1-carboxamide from *Pseudomonas aeruginosa* PAO1. *J bacteriol.* 2001; 183(21): 6454-6465. doi: 10.1128/JB.183.21.6454-6465.2001
13. Ahuja EG, Goody RS, Blankenfeldt W. Towards Elucidation of the Phenazine Biosynthesis Pathway with the Structural and Functional Analysis of the enzymes PhzA, PhzB, PhzG and BcepA. *Doctoral dissertation, Universität Dortmund Dortmund.* 2006. doi: 10.17877/DE290R-5049
14. Gohain N, Thomashow LS, Mavrodi DV, Blankenfeldt W. The purification, crystallization and preliminary structural characterization of PhzM, a phenazine-modifying methyltransferase from *Pseudomonas aeruginosa*. *Acta crystallographica sec F: structural biol crystallization communi.* 2006; 62(9): 887-890. doi: 10.1107/S1744309106029149

15. Waksman SA, Woodruff HB. The soil as a source of microorganisms antagonistic to disease-producing bacteria. *J Bacteriol.* 1940; 40(4), 581-600.
16. Baron SS, Rowe JJ. Antibiotic action of pyocyanin. *Antimicrob agents and chemother.* 1981; 20(6): 814-820.
17. Baron SS, Terranova G, Rowe JJ. Molecular mechanism of the antimicrobial action of pyocyanin. *Current microbiology.* 1989; 18(4): 223-230.
18. Hassan HM, Fridovich I. Mechanism of the antibiotic action pyocyanine. *J Bacteriol.* 1980; 141(1): 156-163.
19. Machan ZA, Pitt TL, White W, et al. Interaction between *Pseudomonas aeruginosa* and *Staphylococcus aureus*: description of an antistaphylococcal substance. *J Med Microbiol.* 1991; 34(4): 213-217. doi: 10.1099/00222615-34-4-213.
20. Saha S, Thavasi R, Jayalakshmi S. Phenazine pigments from *Pseudomonas aeruginosa* and their application as antibacterial agent and food colourants. *Res J Microbiol.* 2008; 3(3): 122-128. doi: 10.3923/jm.2008.122.128
21. Fontoura R, Spada JC, Silveira ST, Tsai SM, Brandelli A. Purification and characterization of an antimicrobial peptide produced by *Pseudomonas* sp. strain 4B. *World J Microbiol and Biotechnol.* 2009; 25(2): 205-213.
22. Rahman PK, Pasirayi G, Auger V, Ali Z. Development of a simple and low cost microbioreactor for high-throughput bioprocessing. *Biotechnol lett.* 2009; 31(2): 209-214. doi: 10.1007/s10529-008-9853-8
23. Kerr JR. Suppression of fungal growth exhibited by *Pseudomonas aeruginosa*. *J Clin Microbiol.* 1994; 32(2): 525-527.
24. Kerr JR, Taylor GW, Rutman A, Høiby N, Cole PJ, Wilson R. *Pseudomonas aeruginosa* pyocyanin and 1-hydroxyphenazine inhibit fungal growth. *J Clin Pathol.* 1999; 52(5), 385-387.
25. Jorgensen JH, Pfaller MA. Manual of Clinical Microbiology. Volumes 1 and 2. 11th edition. In: Carroll KC, Landry ML, Funke G, Richter SS, Warnock DW (eds.). American Society for Microbiology: ASM Press. Washington, D.C. 2015.
26. Wilson R, Pitt T, Taylor G, et al. Pyocyanin and 1-hydroxyphenazine produced by *Pseudomonas aeruginosa* inhibit the beating of human respiratory cilia in vitro. *J Clin Invest.* 1987; 79(1): 221-229. doi: 10.1172/JCI112787
27. Raji El Feghali P, NawasT. Extraction and purification of pyocyanin: a simpler and more reliable method. *MOJ Toxicol.* 2018; 4(6): 417-422. doi: 10.15406/mojt.2018.04.00139
28. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement. M100-S24. Wayne, PA: Clinical and Laboratory Standards Institute. 2014.
29. Perez C, Paul M, Bazerque P. An Antibiotic assay by the agar well diffusion method. *Acta. Biol. Med. Exp.* 1990; 15:113-115. doi: 10.4236/psych.2011.27108
30. Mathur T, Singhal S, Khan S, Upadhyay DJ, Fatma T, Rattan A. Detection of biofilm formation among the clinical isolates of staphylococci: an evaluation of three different screening methods. *Indian J Med Microbiol.* 2006; 24(1):25-29.
31. Sweedan EG. Study the effect of antibiotics on pyocyanin production from *Pseudomonas aeruginosa* and pyocyanin as antibiotic against different pathogenic bacteria. *J Univer Anbar for Pure Sci.* 2010; 4(1), 15-18.
32. El-Shouny WA, Al-Baidani ARH, Hamza WT. Antimicrobial activity of pyocyanin produced by *Pseudomonas aeruginosa* isolated from surgical wound-infections. *Inter J Pharm and Med Sci.* 2011; 1(1): 01-07.
33. Khoury AE, Lam K, Ellis B, Costerton JW. Prevention and control of bacterial infections associated with medical devices. *ASAIO J.* 1992; 38(3): 174-178.